Trial Profile
Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 26 May 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2025.
- 26 May 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2025.
- 14 Sep 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.